Abstract
During the last decade, a growing body of evidence has shown an interplay of genetics and inflammation which leads to a greater understanding of the complex pathophysiology of atherosclerotic vascular disease. Of great interest are non-coding RNAs, called microRNAs due to their importance for many aspects of homeostasis and disease. According significant data, they have been implicated in the regulation of several human physiological processes, while they seem to participate in cardiovascular disease pathogenesis including atherosclerosis and acute coronary syndromes. Accordingly, other biomarkers beyond troponins such as microRNAs, could be proved very useful in the aim of enhancing diagnostic or therapeutic effectiveness. Notably, there is evidence that patients with unstable angina pectoris could be discriminated from stable patients, given higher expression levels of several microRNAs, suggesting that they could be used to identify patients at risk for acute coronary syndromes. Also, they may have a substantial therapeutic impact in the management of athero-thrombotic vascular disorders, even though there are still obstacles in their use for that purposes, such as the delivery of the drug to target cells. Thus, it will be necessary to further explore their complications, before their use as therapeutic option.
Keywords: microRNAs, unstable angina, atherosclerosis, diagnosis, biomarkers treatment.
Current Topics in Medicinal Chemistry
Title:MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Volume: 13 Issue: 13
Author(s): George Latsios, Dimitris Tousoulis, Emmanuel Androulakis, Nikolaos Papageorgiou, Andreas Synetos, Konstantinos Toutouzas, Gerasimos Siasos, Evangelos Oikonomou and Christodoulos Stefanadis
Affiliation:
Keywords: microRNAs, unstable angina, atherosclerosis, diagnosis, biomarkers treatment.
Abstract: During the last decade, a growing body of evidence has shown an interplay of genetics and inflammation which leads to a greater understanding of the complex pathophysiology of atherosclerotic vascular disease. Of great interest are non-coding RNAs, called microRNAs due to their importance for many aspects of homeostasis and disease. According significant data, they have been implicated in the regulation of several human physiological processes, while they seem to participate in cardiovascular disease pathogenesis including atherosclerosis and acute coronary syndromes. Accordingly, other biomarkers beyond troponins such as microRNAs, could be proved very useful in the aim of enhancing diagnostic or therapeutic effectiveness. Notably, there is evidence that patients with unstable angina pectoris could be discriminated from stable patients, given higher expression levels of several microRNAs, suggesting that they could be used to identify patients at risk for acute coronary syndromes. Also, they may have a substantial therapeutic impact in the management of athero-thrombotic vascular disorders, even though there are still obstacles in their use for that purposes, such as the delivery of the drug to target cells. Thus, it will be necessary to further explore their complications, before their use as therapeutic option.
Export Options
About this article
Cite this article as:
Latsios George, Tousoulis Dimitris, Androulakis Emmanuel, Papageorgiou Nikolaos, Synetos Andreas, Toutouzas Konstantinos, Siasos Gerasimos, Oikonomou Evangelos and Stefanadis Christodoulos, MicroRNAs in the Diagnosis and Treatment of Unstable Angina, Current Topics in Medicinal Chemistry 2013; 13 (13) . https://dx.doi.org/10.2174/15680266113139990108
DOI https://dx.doi.org/10.2174/15680266113139990108 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Human Urotensin II and Metabolic Syndrome
Vascular Disease Prevention (Discontinued) Human Platelet-Derived Growth Factor Enhances Healing of Ulcers Situated on Non-Foot Sites in Diabetics. A Pilot Study
Current Drug Therapy Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology α-Fibrinogenases
Current Drug Targets - Cardiovascular & Hematological Disorders Prasugrel: A Novel Antiplatelet Therapy for Acute Coronary Syndromes
Recent Patents on Cardiovascular Drug Discovery Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Current Vascular Pharmacology Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Clinical Aspects and Therapeutic Perspectives of Relaxin
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Editorial [Hot Topic: The Clinical Management and Treatment of Hypertension, Its Pathophysiology and the Clinical Use of Antihypertensive Drugs (Executive Editor: Gregory Y.H. Lip)]
Current Pharmaceutical Design Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Biodegradable and Bioabsorbable Stents
Current Pharmaceutical Design Laser Treatment for Diabetic Macular Edema in the 21<sup>st</sup> Century
Current Diabetes Reviews Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Bio Molecular Considerations in Major Depression and Ischemic Cardiovascular Disease
Central Nervous System Agents in Medicinal Chemistry Pharmacologic Modulators of Soluble Guanylate Cyclase/Cyclic Guanosine Monophosphate in the Vascular System - From Bench Top to Bedside
Current Vascular Pharmacology